A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

OBJECTIVES: To compare the pharmacokinetics (PK), safety and efficacy of innovator infliximab (INX) and CT-P13, a biosimilar to INX, in patients with active ankylosing spondylitis (AS). METHODS: Phase 1 randomised, double-blind, multicentre, multinational, parallel-group study. Patients were randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Won, Hrycaj, Pawel, Jeka, Slawomir, Kovalenko, Volodymyr, Lysenko, Grygorii, Miranda, Pedro, Mikazane, Helena, Gutierrez-Ureña, Sergio, Lim, MieJin, Lee, Yeon-Ah, Lee, Sang Joon, Kim, HoUng, Yoo, Dae Hyun, Braun, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786643/
https://www.ncbi.nlm.nih.gov/pubmed/23687259
http://dx.doi.org/10.1136/annrheumdis-2012-203091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786643/
https://www.ncbi.nlm.nih.gov/pubmed/23687259
http://dx.doi.org/10.1136/annrheumdis-2012-203091

Ejemplares similares